The post-hoc analysis sought to identify factors predictive of relapse and disability progression in people with MS enrolled in the TRANSFORMS study.
Researchers sought to determine whether treatment with ocrelizumab improved measures of cognitive function better than interferon beta 1-a.
Initial trials of teriflunomide have demonstrated low lymphocyte counts in patients with relapsing forms of MS.
In patients with MS, hand function often correlates with measures of quality of life.
The prevalence of osteoporosis was greater in patients with MS than in matched controls.
Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.
Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies